Heather Berger

Heather is a biotechnology investor most recently at SR One Capital management. She joined SR One in the Spring of 2019, and has been involved in investments in MiroBio, Dren Bio, ARS Pharma, Mineralys and Design Therapeutics where she is a board member. Previously, she worked as a Principal at Sofinnova Ventures, and prior to that, as an Equity Research Analyst at two boutique Investment Banks. Heather was formally a chemist at the Astellas Research Institute and Adjunct Faculty at Northwestern University. She received her Ph.D. in Chemistry at Northwestern University, MSc. in Organic Chemistry at the Weizmann Institute of Science, and BS from Tufts University.